Diabetes, Obesity and Metabolism

Top Research Topics at Diabetes, Obesity and Metabolism?

The journal mainly tackles studies in Internal medicine, Type 2 diabetes, Endocrinology, Diabetes mellitus and Insulin. Topics in Internal medicine explored in it were investigated in conjunction with research in Gastroenterology and Placebo. The journal focuses on Placebo research which is adjacent to topics in Tolerability.

It focuses on Type 2 diabetes but the discussions also offer insight into other areas such as Adverse effect, Pharmacology and Type 2 Diabetes Mellitus. Pharmacokinetics is a primary topic of Pharmacology research in Diabetes, Obesity and Metabolism. Postprandial, Body mass index, Weight loss, Obesity and Glucagon are all aspects of Endocrinology research featured in it.

In it, Clinical trial, Surgery, Blood pressure, Intensive care medicine and Disease are investigated in conjunction with one another to address concerns in Diabetes mellitus research. Insulin research discussed connects with the study of Type 1 diabetes. The journal centers on topics in Metformin, with a focus on Sitagliptin.

• Internal medicine (68.58%)
• Type 2 diabetes (44.64%)
• Endocrinology (36.48%)

What are the most cited papers published in the journal?

• Efficacy and safety of the dipeptidyl peptidase‐4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double‐blind, non‐inferiority trial (605 citations)
• Pancreatic beta-cell mass in European subjects with type 2 diabetes. (582 citations)
• Adiponectin--a key adipokine in the metabolic syndrome. (508 citations)

Research areas of the most cited articles at Diabetes, Obesity and Metabolism:

The most cited articles are organized to address concerns in the fields of Internal medicine, Endocrinology, Type 2 diabetes, Diabetes mellitus and Insulin. The most cited publications address concerns in Internal medicine which are intertwined with other disciplines, such as Gastroenterology and Placebo. While the primary focus in the journal publications is Type 2 diabetes, they also dissect topics surrounding Pharmacology and Vildagliptin and Incretin as a whole.

What topics the last edition of the journal is best known for?

• Internal medicine
• Gene
• Diabetes mellitus

The previous edition focused in particular on these issues:

The topics of Internal medicine, Type 2 diabetes, Diabetes mellitus, Type 1 diabetes and In patient are the focal point of discussions in the journal. Topics in Internal medicine were tackled in line with various other fields like Gastroenterology, Placebo and Endocrinology. The research on Placebo featured in Diabetes, Obesity and Metabolism combines topics in other fields like Body mass index, Adverse effect and Dapagliflozin.

Endocrinology research is concerned with Postprandial in particular. Aside from discussions in Type 2 diabetes, it also deals with the subject of Post-hoc analysis which intersects with Oncology disciplines. Research in Hazard ratio and the interrelating topic of Proportional hazards model and Cohort study were among the subjects of interest in the Diabetes mellitus studies discussed in the journal.

The most cited articles from the last journal are:

• Proportion of newly diagnosed diabetes in COVID-19 patients: a systematic review and meta-analysis (34 citations)
• Obesity as a risk factor for COVID-19 mortality in women and men in the UK Biobank: comparisons with influenza/pneumonia and coronary heart disease (28 citations)
• Relationship between obesity and severe COVID-19 outcomes in patients with type 2 diabetes: Results from the CORONADO study. (26 citations)

Papers citation over time

A key indicator for each journal is its effectiveness in reaching other researchers with the papers published at that venue.

The chart below presents the interquartile range (first quartile 25%, median 50% and third quartile 75%) of the number of citations of articles over time.

Top authors and change over time

The top authors publishing in Diabetes, Obesity and Metabolism (based on the number of publications) are:

• Kamlesh Khunti (103 papers) published 24 papers at the last edition the same number as at the previous edition,
• Melanie J. Davies (82 papers) published 11 papers at the last edition, 4 less than at the previous edition,
• Hiddo J.L. Heerspink (60 papers) published 11 papers at the last edition, 8 less than at the previous edition,
• Julio Rosenstock (53 papers) published 9 papers at the last edition, 3 less than at the previous edition,
• Tim Heise (53 papers) published 2 papers at the last edition, 2 less than at the previous edition.

The overall trend for top authors publishing in this journal is outlined below. The chart shows the number of publications at each edition of the journal for top authors.

Top affiliations and change over time

Only papers with recognized affiliations are considered

The top affiliations publishing in Diabetes, Obesity and Metabolism (based on the number of publications) are:

• Novo Nordisk (224 papers) published 35 papers at the last edition, 17 more than at the previous edition,
• University of Copenhagen (171 papers) published 27 papers at the last edition, 9 more than at the previous edition,
• AstraZeneca (159 papers) published 22 papers at the last edition, 1 less than at the previous edition,
• Eli Lilly and Company (138 papers) published 16 papers at the last edition, 2 more than at the previous edition,
• University of Toronto (111 papers) published 21 papers at the last edition, 2 more than at the previous edition.

The overall trend for top affiliations publishing in this journal is outlined below. The chart shows the number of publications at each edition of the journal for top affiliations.

Publication chance based on affiliation

The publication chance index shows the ratio of articles published by the best research institutions in the journal edition to all articles published within that journal. The best research institutions were selected based on the largest number of articles published during all editions of the journal.

The chart below presents the percentage ratio of articles from top institutions (based on their ranking of total papers).Top affiliations were grouped by their rank into the following tiers: top 1-10, top 11-20, top 21-50, and top 51+. Only articles with a recognized affiliation are considered.

During the most recent 2021 edition, 54.38% of publications had an unrecognized affiliation. Out of the publications with recognized affiliations, 39.55% were posted by at least one author from the top 10 institutions publishing in the journal. Another 11.02% included authors affiliated with research institutions from the top 11-20 affiliations. Institutions from the 21-50 range included 15.82% of all publications and 33.62% were from other institutions.

Returning Authors Index

A very common phenomenon observed among researchers publishing scientific articles is the intentional selection of journals they have already attended in the past. In particular, it is worth analyzing the case when the authors participate in the same journal from year to year.

The Returning Authors Index presented below illustrates the ratio of authors who participated in both a given as well as the previous edition of the journal in relation to all participants in a given year.

Returning Institution Index

The graph below shows the Returning Institution Index, illustrating the ratio of institutions that participated in both a given and the previous edition of the conference in relation to all affiliations present in a given year.

The experience to innovation index

Our experience to innovation index was created to show a cross-section of the experience level of authors publishing in a journal. The index includes the authors publishing at the last edition of a journal, grouped by total number of publications throughout their academic career (P) and the total number of citations of these publications ever received (C).

The group intervals were selected empirically to best show the diversity of the authors' experiences, their labels were selected as a convenience, not as judgment. The authors were divided into the following groups:

• Novice - P < 5 or C < 25 (the number of publications less than 5 or the number of citations less than 25),
• Competent - P < 10 or C < 100 (the number of publications less than 10 or the number of citations less than 100),
• Experienced - P < 25 or C < 625 (the number of publications less than 25 or the number of citations less than 625),
• Master - P < 50 or C < 2500 (the number of publications less than 50 or the number of citations less than 2500),
• Star - P ≥ 50 and C ≥ 2500 (both the number of publications greater than 50 and the number of citations greater than 2500).

The chart below illustrates experience levels of first authors in cases of publications with multiple authors.

Additional Educational Resources

For those looking into furthering their knowledge on endocrinology, internal medicine, or diabetes care, there are various resources available. One potential path is studying licensed practical nursing as a foundational education in healthcare, which can include these topics. For instance, lpn programs vermont is an overview of certain programs that may interest prospective students. Such programs typically cover a broad range of medical topics, including endocrinology and diabetes care, which can provide a solid basis for further specialization in metabolic research.